These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26264175)

  • 1. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
    Anoosha P; Huang LT; Sakthivel R; Karunagaran D; Gromiha MM
    Mutat Res; 2015 Oct; 780():24-34. PubMed ID: 26264175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Driver Missense Mutation Identification Using Feature Selection and Model Fusion.
    Soliman AT; Meng T; Chen SC; Iyengar SS; Iyengar P; Yordy J; Shyu ML
    J Comput Biol; 2015 Dec; 22(12):1075-85. PubMed ID: 26402258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the functional consequences of somatic missense mutations found in tumors.
    Carter H; Karchin R
    Methods Mol Biol; 2014; 1101():135-59. PubMed ID: 24233781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.
    Anoosha P; Sakthivel R; Gromiha MM
    Mutat Res; 2017 Dec; 806():19-26. PubMed ID: 28938109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for EGFR mutations in lung cancer, a report from India.
    Sahoo R; Harini VV; Babu VC; Patil Okaly GV; Rao S; Nargund A; Venkataswamy E; Rao R; Kumar BS
    Lung Cancer; 2011 Sep; 73(3):316-9. PubMed ID: 21315473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
    Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
    BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.
    Chen Z; Feng J; Saldivar JS; Gu D; Bockholt A; Sommer SS
    Oncogene; 2008 Jul; 27(31):4336-43. PubMed ID: 18372921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDMPred: a tool for predicting cancer driver missense mutations with high-quality passenger mutations.
    Wang L; Sun H; Yue Z; Xia J; Li X
    PeerJ; 2024; 12():e17991. PubMed ID: 39253604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing.
    Zhang J; Liu J; Sun J; Chen C; Foltz G; Lin B
    Brief Bioinform; 2014 Mar; 15(2):244-55. PubMed ID: 23818492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
    Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
    ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
    Rajasekaran R; Sethumadhavan R
    Appl Biochem Biotechnol; 2010 Mar; 160(6):1723-33. PubMed ID: 19455431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets.
    Anoosha P; Sakthivel R; Michael Gromiha M
    Biochim Biophys Acta; 2016 Feb; 1862(2):155-65. PubMed ID: 26581171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
    Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
    Elife; 2021 Jan; 10():. PubMed ID: 33427197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.
    Franco-Hernandez C; Martinez-Glez V; Arjona D; de Campos JM; Isla A; Gutierrez M; Vaquero J; Rey JA
    Cancer Genet Cytogenet; 2007 Feb; 173(1):63-7. PubMed ID: 17284372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.